Summary
Abbott Laboratories reported a solid increase in net sales for the second quarter and first six months of 2025, driven primarily by strong performance in its Medical Devices and Established Pharmaceutical Products segments. Total net sales grew by 7.4% in Q2 and 5.7% year-to-date, with growth largely excluding the impact of foreign exchange. The company's profitability saw an improvement, with gross profit margin increasing to 52.7% for both periods, reflecting successful margin improvement initiatives. While the Diagnostic Products segment experienced a decline, largely due to the continued decrease in COVID-19 testing sales, the growth in other segments, particularly Medical Devices with notable strength in Diabetes Care, Heart Failure, and Structural Heart, signals a healthy underlying business. Financially, Abbott maintained a strong liquidity position with $7.0 billion in cash and cash equivalents at the end of the period. The company also continued its commitment to returning value to shareholders through dividend payments and share repurchases, with a significant authorization for future buybacks. Management highlighted ongoing investments in research and development to fuel future growth and successfully managed operating expenses despite increased spending in sales and marketing. The company is also navigating potential legal and tax matters, including ongoing IRS disputes, but management expressed confidence in their ability to manage these issues without material adverse effects on the company's financial standing.
Financial Highlights
51 data points| Revenue | $11.14B |
| Cost of Revenue | $4.85B |
| Gross Profit | $6.29B |
| R&D Expenses | $725.00M |
| SG&A Expenses | $3.09B |
| Operating Expenses | $9.09B |
| Operating Income | $2.05B |
| Net Income | $1.78B |
| EPS (Basic) | $1.02 |
| EPS (Diluted) | $1.01 |
| Shares Outstanding (Basic) | 1.74B |
| Shares Outstanding (Diluted) | 1.75B |
Key Highlights
- 1Total net sales increased by 7.4% in Q2 2025 and 5.7% for the first six months of 2025 compared to the prior year, with significant growth excluding foreign exchange impacts.
- 2Medical Devices segment showed robust growth, up 13.4% in Q2 and 11.7% year-to-date (excluding foreign exchange), driven by strong performance in Diabetes Care, Heart Failure, and Structural Heart.
- 3Established Pharmaceutical Products segment also saw solid growth, with sales up 6.9% in Q2 and 4.9% year-to-date (excluding foreign exchange), particularly in emerging markets.
- 4Gross profit margin improved to 52.7% for Q2 and year-to-date 2025, up from 51.1% and 50.8% respectively in the prior year periods.
- 5Diagnostic Products segment sales declined by 1.0% in Q2 and 4.1% year-to-date, largely due to a significant decrease in COVID-19 testing-related sales.
- 6The company maintained a strong cash position, with $7.0 billion in cash and cash equivalents, and generated $3.5 billion in net cash from operating activities for the first six months of 2025.
- 7Abbott continues to return capital to shareholders, with a quarterly dividend of $0.59 per share declared and an authorization for up to $7 billion in share repurchases.